Pharmaceuticals US

US Non-Hormonal Menopause Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

US Non-Hormonal Menopause Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.03 Bn Placeholder estimate
Estimate 2025 $1.17 Bn 45.9% of the global market
Projected 2034 $3.78 Bn 222.6% Adds $2.61 Bn over 9 forecast years
CAGR 2025–2034 13.9% Faster than 79% of 180 Pharmaceuticals markets here
Key players 4
  • US is 45.87% of the global market.
  • In North America, the largest is US (this report) at $1.17 Bn.
  • Fastest growing: Canada at 16% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.61 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Non-Hormonal Menopause Drugs Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.03 Bn — —
2025 (base) $1.17 Bn +$143.1 Mn —
2026 (forecast) $1.34 Bn +$163.0 Mn +13.9%
2027 (forecast) $1.52 Bn +$185.7 Mn +29.7%
2028 (forecast) $1.73 Bn +$211.5 Mn +47.8%
2029 (forecast) $1.97 Bn +$240.9 Mn +68.3%
2030 (forecast) $2.25 Bn +$274.3 Mn +91.7%
2031 (forecast) $2.56 Bn +$312.5 Mn +118.3%
2032 (forecast) $2.92 Bn +$355.9 Mn +148.7%
2033 (forecast) $3.32 Bn +$405.4 Mn +183.3%
2034 (forecast) $3.78 Bn +$461.7 Mn +222.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Non-Hormonal Menopause Drugs Market Analysis at a glance
Market size, 2025$1.17 Bn placeholder estimate
Forecast, 2034$3.78 Bn placeholder estimate
Growth (CAGR), 2025–203413.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, indication and end user (see all)
Key playersAstellas Pharma Inc., Bayer AG, Pfizer Inc., Noven Pharmaceuticals (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials26 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Non-Hormonal Menopause Drugs Market Analysis Executive Summary

Non-hormonal menopause drugs treat hot flashes and night sweats without estrogen, for women who cannot or prefer not to use hormone therapy.

Key segments of the non-Hormonal Menopause Drugs market include drug class (NK3 Receptor Antagonists, SSRIs and SNRIs and Gabapentinoids) and indication (Hot Flashes and Sleep Disturbance).

Bar chart: US Non-Hormonal Menopause Drugs market size, 2024–2034, placeholder estimates. $1.03 Bn in 2024, $1.17 Bn in 2025 and $3.78 Bn in 2034, 13.9% CAGR.
US Non-Hormonal Menopause Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Non-Hormonal Menopause Drugs Market Dynamics

Market Growth Drivers

Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the non-Hormonal Menopause Drugs market. New products designed around women's biology and digital care are improving access.

Opportunity

Femtech, personalised care and new treatments for under-served conditions open strong growth for the non-Hormonal Menopause Drugs market, especially as employers and payers add women's health benefits.

Market Restraints

Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the non-Hormonal Menopause Drugs market.

Competitive Landscape for Non-Hormonal Menopause Drugs Market in US

The non-Hormonal Menopause Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Non-Hormonal Menopause Drugs Market in US

Non-Hormonal Menopause Drugs in the US: rules, payment and research

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 26 studies on Non-Hormonal Menopause Drugs that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for non-Hormonal Menopause Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Non-Hormonal Menopause Drugs right now, from free public sources.

Clinical trials

26 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Bayer AG 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. SRI International 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Non-Hormonal Menopause Drugs in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Non-Hormonal Menopause Drugs market in the US?
Placeholder estimate: about $1.17 Bn in 2025, rising to about $3.78 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Non-Hormonal Menopause Drugs market in the US growing?
Placeholder estimate: about 13.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Non-Hormonal Menopause Drugs market report cover?
The report splits the market by drug class (NK3 Receptor Antagonists, SSRIs and SNRIs, Gabapentinoids, Others), indication (Hot Flashes, Sleep Disturbance) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Non-Hormonal Menopause Drugs market?
Key players include Astellas Pharma Inc., Bayer AG, Pfizer Inc. and Noven Pharmaceuticals.
What is driving the Non-Hormonal Menopause Drugs market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the non-Hormonal Menopause Drugs market. New products designed around women's biology and digital care are improving access.
Who regulates Non-Hormonal Menopause Drugs in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Non-Hormonal Menopause Drugs are running in the US?
26 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Non-Hormonal Menopause Drugs?
PubMed lists 13 papers on Non-Hormonal Menopause Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on women's health

See the topic